HAVCR2 and neoplasm: Bachiller et al. combined CAR-T cell therapy with a low-dose infusion of expanded NK cells and revealed that NK cells promote early activation of CAR-T cells, enhance migration to tumor cells, and decrease the expression of the depletion markers PD-1, TIM3, and LAG-3 in CAR+ and CAR-T cells (Bachiller et al., 2021).